MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


GSK seeks FDA green light for expanded use of RSV vaccine Arexvy

ALN

GSK PLC on Monday said it has submitted a US regulatory application for the expanded use of its Arexvy respiratory syncytial virus vaccine.

The London-based drug maker said the US Food & Drug Administration has accepted for review an application to extend the indication of Arexvy to adults aged between 18 and 49 who are at ‘an increased risk’.

The jab is currently approved in the US for the prevention of respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 who are most at risk.

The submission was supported by positive phase IIIb data showing immune response and safety results in adults aged 18-49 at increased risk compared to adults aged 60 and above.

The safety data were consistent with results from the phase III programme that supported the initial approval of the vaccine in the US.

‘A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic Area and Japan,’ GSK said.

Shares in GSK rose 0.6% to 1,417.50 pence each in London on Monday morning. The wider FTSE 100 was up 0.2%.

Copyright 2025 Alliance News Ltd. All Rights Reserved.